Lipopolysaccharide pre-treatment induces resistance against subsequent focal cerebral ischemic damage in spontaneously hypertensive rats

K Tasaki; C A Ruetzler; T Ohtsuki; D Martin; H Nawashiro; J M Hallenbeck

doi:10.1016/s0006-8993(96)01383-2

Lipopolysaccharide pre-treatment induces resistance against subsequent focal cerebral ischemic damage in spontaneously hypertensive rats

Brain Res. 1997 Feb 14;748(1-2):267-70. doi: 10.1016/s0006-8993(96)01383-2.

Authors

K Tasaki¹, C A Ruetzler, T Ohtsuki, D Martin, H Nawashiro, J M Hallenbeck

Affiliation

¹ Stroke Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892-4128, USA.

PMID: 9067475
DOI: 10.1016/s0006-8993(96)01383-2

Abstract

Ischemic tolerance was induced in spontaneously hypertensive rats (SHR) by injection of a single dose of lipopolysaccharide (LPS) (0.9 mg/kg, i.v.) 1-7 days prior to permanent middle cerebral artery occlusion (MCAO). Infarct volume, evaluated 24 h after MCAO, was significantly reduced by LPS administration 2, 3 or 4 days prior to MCAO (22.8, 25.9 and 20.5%, respectively). The beneficial effect of LPS pre-treatment was completely nullified by concurrent administration of TNFbp. On this basis, the tolerance to ischemia induced by LPS is likely to be mediated by TNF-alpha.

MeSH terms

Animals
Brain Ischemia / pathology*
Brain Ischemia / prevention & control*
Carrier Proteins / pharmacology
Cerebral Infarction / pathology
Hypertension / physiopathology*
Lipopolysaccharides / pharmacology*
Male
Rats
Rats, Inbred SHR / physiology*
Receptors, Tumor Necrosis Factor*
Receptors, Tumor Necrosis Factor, Type I
Tumor Necrosis Factor Decoy Receptors

Substances

Carrier Proteins
Lipopolysaccharides
Receptors, Tumor Necrosis Factor
Receptors, Tumor Necrosis Factor, Type I
Tumor Necrosis Factor Decoy Receptors
recombinant human tumor necrosis factor-binding protein-1